Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago.
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni Benjamin - Citizens JMP David Dai - UBS Andrew Tsai - Jefferies Operator Good day and thank you for standing by. Welcome everyone to the Iovance Biotherapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
What's in Store for These 5 Biotech Stocks This Earnings Season?
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Wrong With Iovance Biotherapeutics Stock?
It was about a year ago that shares of Iovance Biotherapeutics (IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as a treatment option for patients with unresectable or metastatic melanoma.
